Related Experiment Videos
Pancreatic endocrine tumors: an update
1Department of Pathology, University Health Network/Toronto Medical Laboratories, University of Toronto, Toronto, Canada.
Advances in Anatomic Pathology
|June 29, 2004
Summary
Pancreatic endocrine tumors (PETs) often present subtly in adults and can be functional, causing hormone excess syndromes. Genetic factors and chromosomal abnormalities, like 11q loss, influence their development and prognosis.
Area of Science:
- Endocrinology
- Oncology
- Genetics
Background:
- Pancreatic endocrine tumors (PETs) share morphological similarities with other endocrine neoplasms.
- PETs typically affect adults and can manifest clinically through hormone excess syndromes, though subclinical presentations are possible.
Purpose of the Study:
- To review the characteristics, origins, and genetic underpinnings of pancreatic endocrine tumors.
- To highlight the importance of recognizing subtle clinical manifestations of PETs.
Main Methods:
- Review of existing literature on pancreatic endocrine tumor morphology, clinical presentation, and genetics.
- Analysis of hereditary and sporadic PET associations, including genetic loci and chromosomal abnormalities.
Main Results:
- PETs arise from stem cells or endocrine cells and can be hereditary (MEN-1, VHL, NF, TS) or sporadic.
- Allelic loss on chromosome 11q is a common abnormality in sporadic PETs.
- Loss of a sex chromosome correlates with increased metastasis, local invasion, and poorer survival.
Conclusions:
- Understanding the diverse origins and genetic landscape of PETs is crucial for diagnosis and management.
- Subtle clinical signs of hormone excess should not be overlooked in potential PET cases.
- Chromosomal abnormalities, particularly sex chromosome loss, are significant prognostic indicators in PETs.